Navigation Links
TGen and Ventana Medical Systems Inc. join forces to fight cancer
Date:6/25/2013

PHOENIX, Ariz. June 25, 2013 The Translational Genomics Research Institute (TGen) and Ventana Medical Systems, Inc. (Ventana), a member of the Roche Group, today announced a collaborative research agreement to discover and develop diagnostic markers for treating cancer. The two Arizona-based institutions will leverage each other's expertise in discovery and diagnostic product development, bringing innovative cancer diagnostic tests to patients.

The first project under the umbrella research agreement will focus on diagnostic, prognostic and drug biomarkers for pancreatic cancer, the fourth leading cause of death from cancer in the United States. This year, an estimated 45,000 people will be diagnosed and more than 38,000 patients will die from the disease. Worldwide, more than 213,000 are diagnosed with pancreatic cancer each year, and the numbers are growing. Fewer than 1 in 4 pancreatic cancer patients survive more than a year, and fewer than 6 percent survive more than five years the worst survival rate of any cancer.

This dismal picture of pancreatic cancer is mainly due to the lack of tools for early detection and the ineffectiveness of current therapeutics. This is why new diagnostic markers and more efficacious therapies are desperately needed.

"TGen is on the cutting edge of translational research, where investigators discover the genetic components of disease," says Jeffrey Trent, Ph.D., President and Research Director of TGen. "Our goal is to rapidly translate basic research findings into actionable targets. Partnering with Ventana we hope will accelerate our goal to deliver meaningful discoveries to cancer patients today."

"When a patient is faced with cancer, getting an accurate diagnosis quickly is the most important part of their treatment," says Ventana President and CEO Mara G. Aspinall. "As the global leader in tissue-based cancer diagnostics, our strength is moving research into the clinic in order to impr
'/>"/>

Contact: Steve Yozwiak
syozwiak@tgen.org
602-343-8704
The Translational Genomics Research Institute
Source:Eurekalert

Page: 1 2

Related biology news :

1. U of A medical researchers ID genetic marker for sporadic breast cancer
2. New FASEB analysis documents impact of budget cuts on biomedical research
3. University of Maryland Medical Center launches genetic-testing program for cardiac patients
4. Core for Life, a new European alliance in biomedical research
5. Intermountain Medical Center reseachers develop new 3-D technology to treat atrial fibrillation
6. NYU Langone Medical Center researcher named Howard Hughes Investigator
7. St. Jude scientist named Howard Hughes Medical Institute investigator
8. Using bacteria-eaters to prevent infections on medical implant materials
9. Shared Medical Resources, LLC files suit against Histologics, LLC, Womens Health Laboratories and Avero Diagnostics for Willful Patent Infringement
10. BUSM study shows positive impact of mind-body course on well-being of medical students
11. Quest for edible malarial vaccine leads to other potential medical uses for algae
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... 28, 2015 According to a ... by Assessment Type (Pen & Paper Based, Hosted, Biometrics), ... Learning, Academic Research), Vertical and Region - Global Forecast ... Market to grow from USD 2.4 Billion in 2015 ... Annual Growth Rate (CAGR) of 25.6% from 2015 to ...
(Date:8/26/2015)... PUNE, India , August 26, 2015 ... (Two, Three, Four, and Five Factor), Application (Travel & ... and Geography - Global Forecast to 2020", published by ... 9.60 Billion by 2020, growing at a CAGR of ... 71 Tables and 82 F igures spread through ...
(Date:8/25/2015)... and BELLEVUE, Wash. , ... in advanced robotic systems, announced today it will unveil ... ground vehicle (UGV), at the National Tactical Officers Association ... The Guardian S is the first-ever commercially ... of years of research and in-field trials and is ...
Breaking Biology News(10 mins):Cognitive Assessment and Training Market Worth 7.5 Billion USD by 2020 2Cognitive Assessment and Training Market Worth 7.5 Billion USD by 2020 3Cognitive Assessment and Training Market Worth 7.5 Billion USD by 2020 4Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 2Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 3Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 4Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 5Sarcos to Debut First-of-its-Kind Snake Robot 2Sarcos to Debut First-of-its-Kind Snake Robot 3
... May 26, 2011 Ceelox, Inc. (OTCBB: CELO) announced today ... computers running Windows 7 has earned the "Compatible with Windows ... that Microsoft Corp. has deemed the product compatible with Windows ... to take advantage of the capability of Windows 7.  As ...
... University research team has developed a process that removes ... bacteria. The team has reprogrammed photosynthetic microbes to ... biofuels easier and potentially more commercially viable. ... harvesting the goodies and turning them into fuel," said ...
... that cause neurodegenerative prion diseases may require a genetic ... at Chicago distinguished professor of biological sciences Susan Liebman. ... misfolded form. One prion in mammals promotes progressive neurodegenerative ... But how this process happens remains an open question ...
Cached Biology News:Ceelox Announces "Compatible with Windows 7" Logo for its Ceelox ID 7 for Personal Computers 2Ceelox Announces "Compatible with Windows 7" Logo for its Ceelox ID 7 for Personal Computers 3Green and lean: Secreting bacteria eliminate cost barriers for renewable biofuel production 2Green and lean: Secreting bacteria eliminate cost barriers for renewable biofuel production 3Study finds 2 gene classes linked to new prion formation 2
(Date:8/26/2015)... - iCo Therapeutics ("iCo" or "the Company") (TSX-V: ICO) ... quarter ended June 30, 2015. Amounts, unless specified ... under International Financial Reporting Standards ("IFRS"). ... Oral Amp B program, rapidly advancing towards the ... Rae , President & CEO of iCo Therapeutics. "We ...
(Date:8/26/2015)... ... August 26, 2015 , ... Lee Biosolutions, a global ... and manufacture of highly valued cardiac markers used in early detection of heart ... protein chemistry has led to the development and commercialization of important cardiac biomarkers ...
(Date:8/26/2015)... , Aug. 26, 2015  Platform therapeutic company ... has received a $1.5M Phase II SBIR grant ... further develop its therapeutic agent to reduce arteriovenous ... in end stage renal disease (ESRD) patients undergoing ... Institute of Diabetes and Digestive and Kidney Diseases ...
(Date:8/26/2015)... and BEIJING , August 26, 2015 ... Scene with Impressive Acheivements  DiaCardio wins 1 st ... The competition, led in Israel ... featured 21 startups from countries including the US, China ... and Latin America .  Impressive ...
Breaking Biology Technology:iCo Therapeutics Announces Second Quarter 2015 Financial Results 2iCo Therapeutics Announces Second Quarter 2015 Financial Results 3Lee Biosolutions Announces Increased Investment in the Development and Manufacturing of Biomarkers Used in Early Detection Of Heart Disease 2Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 2Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 3Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 2Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 3Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 4Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 5Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 6
... SAN DIEGO, INDIANAPOLIS, and CAMBRIDGE, Mass., May 5 ... Lilly and Company (NYSE: LLY ) and Alkermes, ... New Drug Application (NDA) for exenatide once weekly has been ... once weekly is an investigational sustained release medication for type ...
... Inc. (Nasdaq: RIGL ) today reported financial results ... quarter of 2009, Rigel reported a net loss of $29.9 ... of $27.3 million, or $0.79 per share, in the first ... quarters of 2009 and 2008 were 36.7 million and 34.4 ...
... separate haves and have-nots and accelerates move to ... turmoil, the global biotechnology industry delivered a solid ... borders: Global biotechnology report 2009 , Ernst & ... However, the prolonged and systemic funding drought is ...
Cached Biology Technology:Exenatide Once Weekly New Drug Application Submitted to FDA for Type 2 Diabetes 2Exenatide Once Weekly New Drug Application Submitted to FDA for Type 2 Diabetes 3Exenatide Once Weekly New Drug Application Submitted to FDA for Type 2 Diabetes 4Exenatide Once Weekly New Drug Application Submitted to FDA for Type 2 Diabetes 5Exenatide Once Weekly New Drug Application Submitted to FDA for Type 2 Diabetes 6Exenatide Once Weekly New Drug Application Submitted to FDA for Type 2 Diabetes 7Rigel Announces First Quarter 2009 Financial Results 2Rigel Announces First Quarter 2009 Financial Results 3Rigel Announces First Quarter 2009 Financial Results 4Rigel Announces First Quarter 2009 Financial Results 5Global Financial Crisis Making Biotech Business Model Unsustainable, According to Ernst & Young 2Global Financial Crisis Making Biotech Business Model Unsustainable, According to Ernst & Young 3Global Financial Crisis Making Biotech Business Model Unsustainable, According to Ernst & Young 4
Rabbit polyclonal to JAK1 (phospho Y1022 + Y1023) ( Abpromise for all tested applications). entrezGeneID: 3716 SwissProtID: P23458...
PCR purification kit, 100 preps...
Rabbit polyclonal to 3-Ethynylestradiol ( Abpromise for all tested applications). Antigen: Ethynylestradiol conjugated to BSA....
... T antigen initiates replication from ... in the presence of the ... can be used in conjunction ... Kit cat. no. 8050. ...
Biology Products: